Entering text into the input field will update the search result below

MDCLF MedinCell S.A.
Stock Price & Overview

$6.980.00 (0.00%)11:31 AM 07/31/23
Expert Market | $USD | Market Close


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

People Also Follow

Company Profile

MedinCell S.A. logo
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company’s products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for organ transplant; mdc-WWM for contraception; mdc-STM for malaria; and mdc-IRM for neuroscience. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.
  • 3 rue des FrEres LumiEre
  • Jacou, 34830
  • France
Phone Number
33 4 67 02 13 67
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.